Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97 [PMID: 33520110 DOI: 10.4239/wjd.v12.i1.84]
Corresponding Author of This Article
Yu-Feng Li, MD, Chief Doctor, Department of Endocrinology, Beijing Friendship Hospital Pinggu Campus, Captital Medical University, No. 59 North Xinping Road, Beijing 101200, China. yflee@bjmu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 2 Comparison of body weight and body mass index changes from baseline in different treatment groups
Studies
Participants
WMD
95%CI
P value
Body weight change
DPP-4 inhibitors
4
140/138
-1.20
-1.44
-0.95
< 0.0001
GLP-1 RAs
8
1222/821
-3.61
-5.74
-1.48
0.0009
SGLT2 inhibitors
5
146/135
-2.53
-3.35
-1.71
< 0.0001
BMI change
DPP-4 inhibitors
5
144/146
-0.59
-1.80
0.61
0.33
GLP-1 RAs
7
251/293
-1.46
-2.23
-0.69
0.0002
SGLT2 inhibitors
4
114/101
-1.72
-2.68
-0.75
0.0005
Table 3 Comparison of hemoglobin A1c change from baseline in different treatment groups
Studies
Participants
WMD
95%CI
P value
HbA1c change
DPP-4 inhibitors
6
166/166
-0.42
-0.58
-0.25
< 0.0001
GLP-1 RAs
7
1210/809
-0.29
-0.85
0.26
0.30
SGLT2 inhibitors
5
146/135
-0.36
-0.80
0.08
0.11
HbA1c change (placebo-controlled studies only)
DPP-4 inhibitors
5
102/102
-0.38
-0.71
-0.05
0.02
GLP-1 RAs
3
1009/566
-0.88
-1.56
-0.19
0.01
SGLT2 inhibitors
1
21/21
-0.50
-0.84
-0.16
0.004
Table 4 Comparison of magnetic resonance imaging proton density fat fraction and visceral fat area change from baseline in different treatment groups
Studies
Participants
WMD
95%CI
P value
MRI-PDFF change
DPP-4 inhibitors
2
52/49
-2.31
-4.92
0.29
0.08
GLP-1 RAs
1
24/24
-3.20
-5.98
-0.42
0.02
SGLT2 inhibitors
2
65/61
-1.18
-2.38
0.03
0.06
VFA change
DPP-4 inhibitors
1
27/24
-23.10
-38.84
-7.36
0.004
GLP-1 RAs
1
24/24
-30.40
-46.86
-13.94
0.0003
SGLT2 inhibitors
2
48/50
-23.48
-25.85
-21.12
< 0.0001
Table 5 Meta-regression analyses of association between weight change difference and difference of alanine aminotransferase, aspartate aminotransferase, magnetic resonance imaging proton density fat fraction, and visceral fat area between antidiabetes drugs and controls (ß coefficient value, P value, and 95%CI are shown)
ß
P value
95%CI
ALT
0.064
0.267
-0.053-0.181
AST
0.020
0.735
-0.104-0.144
MRI-PDFF
0.308
0.701
-2.678-3.294
VFA
1.776
0.343
-11.723-15.275
Citation: Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97